We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tetraphase Pharmaceuticals Inc | NASDAQ:TTPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.22 | 2.31 | 0 | 01:00:00 |
Details for the data presentations at IDWeek 2017 are as follows:
Eravacycline Data Presentations:Poster #1829: Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared to Healthy SubjectsDate and time: Saturday, October 7, 12:30 – 2:00 p.m. PTSession info: 231 - Clinical Study with New Antibiotics and Antifungals, Poster Hall CD
Poster #1832: Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing RegimenDate and time: Saturday, October 7, 12:30 – 2:00 p.m. PTSession info: 231 - Clinical Study with New Antibiotics and Antifungals, Poster Hall CD
Poster #1209: In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.Date and time: Friday, October 6, 12:30 – 2:00 p.m. PTSession info: 147 - Expanded Spectrum – New Antimicrobial Susceptibility Testing, Poster Hall CD
Presentation #866: EravacyclineDate and time: Thursday, October 5, 3:21 p.m. PTSpeaker: Patrick Horn, MD, Ph.D.Session info: Symposium 088: New Antibiotics: What’s in the Pipeline?, Room 20ABCDFollow-up Q&A Session, Friday, October 6, 7:00 – 8:15 a.m. PT; Meet-the-Professor Session 107 – Pipeline 2.0, Room 06DE
Surveillance Data Presentation:Poster #396: Trends in Resistant Enterobacteriaceae (ENT), Acinetobacter baumannii (ACB) and Extended Spectrum Beta-Lactamase (ESBL) Organisms in Hospitalized Patients in the US: 2011-2016Date and time: Thursday, October 5, 12:30 – 2:00 p.m. PTSession info: 052 - HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens, Poster Hall CD
Additional Activities:
IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the ID Week website at http://www.idweek.org/
About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in a phase 3 clinical program, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman617-600-7040tdahlman@tphase.com
Argot PartnersMaeve Conneighton206-899-4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike Beyer312-961-2502Mikebeyer@sambrown.com
1 Year Tetraphase Pharmaceuticals Chart |
1 Month Tetraphase Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions